Denosumab, a RANK ligand inhibitor, for the management of bone loss in cancer patients

被引：29

作者：

Yee, Andrew J. ^{[1
]}

Raje, Noopur S. ^{[1
]}

机构：

[1] Massachusetts Gen Hosp, Ctr Canc, Div Hematol Oncol, Boston, MA 02114 USA

来源：

CLINICAL INTERVENTIONS IN AGING | 2012年 / 7卷

关键词：

denosumab; zoledronic acid; bone loss; breast cancer; prostate cancer; ADJUVANT ENDOCRINE THERAPY; ANDROGEN-DEPRIVATION THERAPY; PLUS ZOLEDRONIC ACID; BREAST-CANCER; POSTMENOPAUSAL WOMEN; PROSTATE-CANCER; DOUBLE-BLIND; OSTEOCLAST DIFFERENTIATION; PREMENOPAUSAL WOMEN; MULTIPLE-MYELOMA;

D O I：

10.2147/CIA.S14566

中图分类号：

R592 [老年病学]; C [社会科学总论];

学科分类号：

03 ; 0303 ; 100203 ;

摘要：

Bone loss is a common side effect of cancer treatments, especially antihormonal treatments used in the treatment of breast and prostate cancer. Denosumab is a monoclonal antibody given subcutaneously that inhibits osteoclast activity by targeting the RANK ligand. It is effective in settings ranging from preventing skeletal-related complications in cancer patients with metastatic disease to increasing bone mineral density in patients with osteoporosis. In cancer patients with early stage disease, denosumab can attenuate bone loss from antihormonal treatments, and in prostate cancer, may reduce disease progression. Here, we will discuss the important role denosumab may play in the management of bone loss in patients with cancer.

引用

页码：331 / 338

页数：8

共 50 条

[1] Denosumab, a RANK ligand Inhibitor, leads to Mineralization of an Intracortical Aneurysmal Bone Cyst
Modaressi, Kourosh
Bode-Lesniewska, Beata
Fuchs, Bruno
[J]. SWISS MEDICAL WEEKLY, 2014, 144 : 53S - 53S
[2] Role of RANK Ligand and Denosumab, a Targeted RANK Ligand Inhibitor, in Bone Health and Osteoporosis: A Review of Preclinical and Clinical Data
Dempster, David W.
Lambing, Cheryl L.
Kostenuik, Paul J.
Grauer, Andreas
[J]. CLINICAL THERAPEUTICS, 2012, 34 (03) : 521 - 536
[3] Increased RANK ligand in bone marrow of orchiectomized rats and prevention of their bone loss by the RANK ligand inhibitor osteoprotegerin
Li, Xiaodong
Ominsky, Michael S.
Stolina, Marina
Warmington, Kelly S.
Geng, Zhaopo
Niu, Qing-Tian
Asuncion, Frank J.
Tan, Hong-Lin
Grisanti, Mario
Dwyer, Denise
Adamu, Steven
Ke, Hua Zhu
Simonet, W. Scott
Kostenuik, Paul J.
[J]. BONE, 2009, 45 (04) : 669 - 676
[4] Denosumab, a RANK Ligand Inhibitor, for Postmenopausal Women with Osteoporosis
Sutton, Emily E.
Riche, Daniel M.
[J]. ANNALS OF PHARMACOTHERAPY, 2012, 46 (7-8) : 1000 - 1009
[5] RANK ligand inhibition with denosumab for the management of osteoporosis
Lewiecki, E. Michael
[J]. EXPERT OPINION ON BIOLOGICAL THERAPY, 2006, 6 (10) : 1041 - 1050
[6] EFFICACY OF DENOSUMAB IN PATIENTS WITH AROMATASE INHIBITOR INDUCED BONE LOSS
Tsagareli, M.
Giorgadze, E.
Khachidze, N.
Dolidze, N.
Sulikashvili, T.
Jeiranashvili, N.
[J]. OSTEOPOROSIS INTERNATIONAL, 2019, 30 : S314 - S314
[7] Rank ligand inhibition in patients with postmenopausal bone loss
Reid, Ian
[J]. BONE, 2009, 44 : S41 - S41
[8] RANK Ligand Inhibitor protects the Bone
Hausmann, Ralph
[J]. ZEITSCHRIFT FUR ORTHOPADIE UND UNFALLCHIRURGIE, 2012, 150 (03): : 246 - 246
[9] Aromatase inhibitor-induced bone loss osteosarcopenia in older patients with breast cancer: effects of the RANK/RANKL system's inhibitor denosumab vs. bisphosphonates
Casabella, Andrea
Paladin, Francesca
Bighin, Claudia
Ottaviani, Silvia
Marelli, Cristina
Ponzano, Marta
Signori, Alessio
Murdaca, Giuseppe
Cutolo, Maurizio
Molfetta, Luigi
Nencioni, Alessio
Paolino, Sabrina
Del Mastro, Lucia
Monacelli, Fiammetta
[J]. INTERNAL AND EMERGENCY MEDICINE, 2024,
[10] RANK LIGAND INHIBITION WITH DENOSUMAB FOR THE MANAGEMENT OF RESISTANT HYPERCALCAEMIA SECONDARY TO BONE MARROW TRANSPLANT IN OSTEOPETROSIS
O' Shea, D.
Brierley, J.
[J]. INTENSIVE CARE MEDICINE, 2011, 37 : S390 - S390

← 1 2 3 4 5 →